Pretomanid has been developed to treat XDR-TB or treatment-intolerant/non-responsive MDR-TB.
It is a nitroimidazole that is designed to be used in combination with bedaquiline and linezolid, as part of the BPaL regimen, according to the manufacturer TB Alliance.
Common side effects include numbness and tingling of extremities, acne, anemia, nausea, vomiting, headache, indigestion, decreased appetite, rash, itching, abdominal pain, sharp chest pain during breathing, lower respiratory tract infections, excess amylase in the blood, coughing up blood, back pain, cough, Visual impairment, low blood sugar, abnormal weight loss, diarrhea, increased gamma-glutamyltransferases and increased transaminases.
Filed Under: Drug Discovery, Drug Discovery and Development, Neurological Disease, Oncology, Orphan Drugs
Tell Us What You Think!
You must be logged in to post a comment.